KPTI News and Press, Karyopharm Therapeutics Inc.

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...

Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...

2024-05-23 06:45:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows o...

2024-05-08 16:45:10 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q1 2024 Earnings Call May 08, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q1 2024 Earnings C...

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference PR Newswire NEWTON, Mass. , May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies...

2024-05-08 15:38:52 ET Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Conference Call May 8, 2024 08:00 ET Company Participants Elhan Webb - Senior Vice President of Investor Relations Richard Paulson - President & Chief Executive Officer Reshma Rangwal...

2024-05-08 11:06:28 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts Karyopharm Therapeutics Q1 2024 Earnings Preview Karyopharm Therapeutics GAAP EPS of -$0.36 misses by $0.07, revenue of $33.7M beats by $0.08M ...

2024-05-08 07:33:56 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript Karyopharm Therapeutics Inc. 2023 Q4 - Results - Earnings Call Presentation ...

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 PR Newswire – $148.0 Million (86%) of Existing Convertible Notes due in 2025 to be Exchanged for $111.0 Millio...

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress PR Newswire – Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and ...